SCHEDULE 13G: HarbourVest Entities Disclose 6.3% Passive Stake in CAMP4 Therapeutics
Beneficial Ownership Disclosure
HarbourVest Partners and its affiliated entities have disclosed a passive beneficial ownership of 6.3% in CAMP4 Therapeutics Corporation, totaling 1,271,948 shares of common stock.
Summary
- HarbourVest Partners L.P., HarbourVest Partners, LLC, SMRS-TOPE LLC, and HVST-TOPE LLC have jointly filed a Schedule 13G, disclosing their beneficial ownership in CAMP4 Therapeutics Corporation.
- The reporting group collectively holds 1,271,948 shares of CAMP4 Therapeutics' common stock.
- This ownership represents 6.3% of the total outstanding common stock of CAMP4 Therapeutics, based on 20,161,072 shares reported by the issuer on March 27, 2025.
- SMRS-TOPE LLC directly owns all 1,271,948 shares with sole voting and dispositive power.
- HarbourVest Partners, LLC, HarbourVest Partners L.P., and HVST-TOPE LLC are deemed to have shared voting and dispositive power due to their managerial and general partner relationships with SMRS-TOPE LLC, though they disclaim beneficial ownership.
- The filing indicates a passive investment purpose, as it was filed under Rule 13d-1(c).
Sentiment
Score: 5
Explanation: A Schedule 13G filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the issuer's performance or outlook. It is a neutral regulatory compliance document.
Future Outlook
NA
Industry Context
This filing indicates a significant institutional investment firm, HarbourVest Partners, has taken a passive stake in CAMP4 Therapeutics Corporation. Such disclosures are common for investment firms managing various funds and portfolios, reflecting their investment strategies in specific companies. The biotech/pharmaceutical industry often sees such institutional investments as companies progress through development stages.
Stakeholder Impact
- Shareholders: The disclosure of a significant stake by an institutional investor like HarbourVest Partners may be viewed positively by existing shareholders, signaling institutional confidence or interest in CAMP4 Therapeutics. It also indicates a notable portion of the company's shares are held by a single investment group.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires the filing of this statement, indicating the reporting period end for the ownership stake. |
| 03/27/2025 | Date CAMP4 Therapeutics Corporation filed its Annual Report on Form 10-K, reporting 20,161,072 shares of common stock outstanding, used as the basis for percentage calculation. |
| 05/14/2025 | Date of the Joint Filing Agreement between the reporting persons and the signature date of the Schedule 13G filing. |
Keywords
CAMP4 Therapeutics Corporation, HarbourVest Partners, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Adviser, Passive Investment, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.